Length of initial prescription at hospital discharge and long-term medication adherence for elderly, post-myocardial infarction patients: a population-based interrupted time series study

J. D. Schwalm1,2†, Noah M. Ivers3,4,5†, Zachary Bouck6, Monica Taljaard7,8, Madhu K. Natarajan1,2, Francis Nguyen5, Waseem Hijazi2, Kednapa Thavorn5,7,9, Lisa Dolovich10, Tara McCready1, Erin O’Brien1 and Jeremy M. Grimshaw7,9

Abstract
Background: Preliminary evidence suggests that providing longer duration prescriptions at discharge may improve long-term adherence to secondary preventative cardiac medications among post-myocardial infarction (MI) patients. We implemented and assessed the effects of two hospital-based interventions—(1) standardized prolonged discharge prescription forms (90-day supply with 3 repeats for recommended cardiac medications) plus education and (2) education only—on long-term cardiac medication adherence among elderly patients post-MI.

Methods: We conducted an interrupted time series study of all post-MI patients aged 65–104 years in Ontario, Canada, discharged from hospital between September 2015 and August 2018 with ≥1 dispensation(s) for a statin, beta blocker, angiotensin system inhibitor, and/or secondary antiplatelet within 7 days post-discharge. The standardized prolonged discharge prescription forms plus education and education-only interventions were implemented at 2 (1,414 patients) and 4 (926 patients) non-randomly selected hospitals in September 2017 for 12 months, with all other Ontario hospitals (n = 143; 18,556 patients) comprising an external control group. The primary outcome, long-term cardiac medication adherence, was defined at the patient-level as an average proportion of days covered (over 1-year post-discharge) ≥80% across cardiac medication classes dispensed at their index fill. Primary outcome data were aggregated within hospital groups (intervention 1, 2, or control) to monthly proportions and independently analyzed using segmented regression to evaluate intervention effects. A process evaluation was conducted to assess intervention fidelity.

Results: At 12 months post-implementation, there was no statistically significant effect on long-term cardiac medication adherence for either intervention—standardized prolonged discharge prescription forms plus education (5.4%;...
Background
Clinical guidelines recommend long-term use of the following cardiac medication classes for secondary prevention in post-myocardial infarction (MI) patients: antiplatelets (aspirin plus a secondary antiplatelet); statins; beta blockers; and angiotensin system inhibitors (i.e., an angiotensin-converting enzyme [ACE] inhibitor or angiotensin receptor blocker [ARB]) [1–3]. These medications are associated with a relative risk reduction of 60% for major cardiovascular events [1, 2]. However, prior research has shown that post-discharge cardiac medication adherence often declines progressively over time [4–13]. Multiple studies have shown an increased risk of morbidity and mortality associated with medication non-adherence in patients with coronary artery disease [11–15].

Observational studies have demonstrated that post-MI patients receiving longer initial prescriptions have greater long-term adherence to cardiac medications [4, 16–18]. Providing longer prescriptions for post-MI patients at the time of discharge could address barriers to medication adherence including prescription refill burden and unintentional forgetfulness due to lack of habituation [19–21]. Unfortunately, health system policies promote shorter prescriptions, with compensation for up to a maximum of 5 refills in 1 year, likely contributing to the fact that only a minority of post-MI patients in Ontario—Canada’s most populous province—receive longer initial prescriptions that cover ≥ 90 days [4, 22, 23]. Therefore, while medication non-adherence is a complex issue, this relatively simple intervention could have significant implications at the population level.

In the present study, our objectives were to evaluate the effects of two hospital-based interventions implemented in Ontario, Canada, between September 2017 and August 2018—(1) standardized prolonged discharge prescription forms (with 90 days and 3 repeats per recommended cardiac medication class) in combination with on-site clinician education about the potential benefits of prolonged prescriptions and (2) on-site clinician education only—on long-term cardiac medication adherence among post-MI patients. We hypothesized that, in comparison to usual care (no intervention), implementation of the study interventions—which promote increased duration of initial discharge prescriptions—would result in a greater proportion of post-MI patients with long-term cardiac medication adherence over time.

Methods
Study design and setting
The Myocardial Infarction Prescription Adherence Duration (MIPAD) study used a non-randomized controlled interrupted time series design to evaluate whether long-term cardiac medication adherence among post-MI patients age ≥ 65 years in Ontario, Canada, discharged from hospital between 1 September 2015 and 31 August 2018 (24 months pre- and 12 months post-intervention) could be improved via clinician-targeted education alone or in combination with standardized prolonged discharge prescription forms for recommended cardiac medications. Our study protocol was published in November 2020 [24]. Study conduct and reporting were guided by quality criteria proposed by Ramsey et al and recommendations by Turner and colleagues for interrupted time series designs [25, 26].

Interventions
We selected six sites across three hospital corporations within the same health region (the Hamilton Niagara Haldimand Brant region) in Ontario, Canada, to implement one of two non-randomly allocated interventions in September 2017 for 12 months. We included all remaining hospitals in Ontario that received no study intervention as a concurrent, external control group [24].
Both interventions are described fully in our protocol [24]. In brief, the first intervention was implemented at two hospital sites (one is a cardiac center, i.e., has a cardiac catheterization lab) within the same corporation and consisted of two components: (1) updated standardized prolonged discharge prescription forms featuring a default 90-day supply with 3 repeats for recommended secondary prevention cardiac medications, which were instituted in all wards where MI patients are managed, and (2) education, which involved regional educational rounds upon implementation to on-site clinicians promoting longer prescription durations (with quarterly email reminders thereafter), in addition to educational outreach (via personal emails and newsletters) to community pharmacies to encourage dispensation of prolonged discharge medications as prescribed. This intervention is referred to as “standardized prolonged discharge prescription forms plus education” hereafter. The second intervention, which was implemented at the other four selected sites (one cardiac center) across two distinct corporations, only involved the educational component (referred to as “education only” hereafter).

Data sources
Data were obtained from population-based administrative databases that were linked using encoded identifiers and analyzed at ICES—a non-profit research institute authorized under Ontario’s health information privacy law to collect and analyze health care and demographic data for health system improvement and evaluation. The databases at ICES include information on demographics, comorbidities, and vital statistics for nearly all of Ontario’s 14.6 million residents, as well as all prescription medication dispensations covered under the province’s public drug funding system (the Ontario Drug Benefit [ODB] program), hospital discharges, emergency department visits, physician billing claims, and cardiac procedures in the province. Specific databases and their applications are detailed explicitly in subsequent sections. Use of ICES data for this study was authorized under section 45 of Ontario’s Personal Health Information Protection Act, which does not require review by a Research Ethics Board.

Participants
The CorHealth Ontario Cardiac Registry captures demographics, comorbidities, and procedure-specific details (including coronary anatomy) for patients who undergo advanced cardiac procedures in Ontario and was used to identify all cardiac catheterization procedures completed between 2 August 2015 and 31 August 2018 for a primary reason of ST-elevated MI (STEMI) or non-ST-elevated MI (NSTEMI) with evidence of significant coronary artery disease (defined as left main artery stenosis ≥50% or major epicardial coronary stenosis ≥70%) [24]. We only retained cardiac catheterization records that met all of the following criteria: (1) performed on an Ontario resident with a valid provincial health card number; (2) non-missing patient discharge/transfer date; (3) patient aged ≥65 years (i.e., age-eligible for prescription drug coverage under the ODB plan) and <105 years old; and (4) patient alive at discharge according to vital information on procedure record and the Registered Persons Database [24]. Restriction to patients aged 65 and older was done to ensure all participants dispensed cardiac medication prescriptions during the study period would be captured in the ODB database, since younger patients (<65 years) pay for their medications out-of-pocket or through private insurance plans unless they qualify for ODB coverage through social support programs. Thus, we excluded patients <65 years of age as we could not access dispensation records for their medications paid in cash or via private insurance. To minimize misclassification around the timing and location (hospital) from which a given patient was discharged, we attempted to link each unique catheterization record by procedure date with an overlapping episode of inpatient care for the same patient (according to Discharge Abstract Database claims) that ended with the patient being discharged home between 1 September 2015 and 31 August 2018. For patients with multiple catheterizations meeting the preceding eligibility criteria, only their first (earliest) catheterization was selected. Using the ODB database, we then restricted our study population to patients with a prescription dispensation claim for at least one recommended cardiac medication class of interest (statin, beta blocker, angiotensin system inhibitor, and/or secondary antiplatelet [i.e., prasugrel, ticagrelor, or clopidogrel]) at their first (“index”) fill within 7 days post-discharge [24]. We did not measure aspirin as it is available without a prescription and, as such, is rarely captured in the ODB database.

Outcomes
Primary outcome
The primary outcome was long-term cardiac medication adherence measured at the patient level using prescription dispensation claims data from the ODB database [24]. For each patient, we identified the number of recommended cardiac medication classes (range, 1–4) dispensed at their index fill. Next, per dispensed class, we calculated the proportion of days covered (PDC) over 1 year from hospital discharge. If patients filled multiple prescriptions for different medications within the same class with overlapping days supplied, we assumed the supply was used in sequence [27]. For patients who died
during follow-up, class-specific PDC values were calculated based on the time elapsed (in days) between discharge and death. Lastly, per patient, we divided the sum of class-specific PDC values by the number of dispensed classes at their index fill to derive that patient’s average PDC across classes. Long-term cardiac medication adherence was defined as an average PDC ≥ 80% [10].

**Secondary outcomes**

Several secondary patient-level outcomes were assessed. At index fill, we separately measured whether the duration (i.e., days supplied) was ≥ 90 days (considered a “prolonged dispensation”) for each dispensed cardiac medication class and whether the average initial duration was ≥ 90 days across all dispensed cardiac medication classes [24].

Additional medication-related secondary outcomes were measured including medication-class specific adherence (PDC ≥ 80%) and persistence (no period of ≥ 30 days without supply) at 1 year from discharge, as well as the number of cardiac medication classes dispensed to a patient at their index fill (range, 1–4) [24].

We also assessed the following health care utilization and adverse clinical outcomes at 1-year post-discharge: frequency of outpatient primary care visits; frequency of outpatient cardiology visits; time-to-hospitalization (in days) for (a) cardiovascular disease, (b) repeat acute MI, (c) stroke; time-to-hospitalization (in days) for (a) repeat cardiac catheterization and (b) coronary revascularization; and time-to-death (all-cause; in days) [24]. Visits or events occurring on the same day as discharge were not counted.

**Statistical analysis**

**Aggregate segmented regression analyses**

Consistent with our published protocol [24], the main analysis of the primary outcome involved aggregating monthly data across all sites within an intervention group and analyzing the resulting monthly proportions (expressed as percentages) using segmented linear regression with first-order autoregressive errors (to account for autocorrelation) and fixed effects for time (in months; treated as continuous), intervention (1: post-implementation; 0: pre-implementation); and time after intervention (in months; treated as continuous). A group-month unit of analysis was chosen to facilitate expression of intervention effects on the absolute difference scale and promote time series stability [24]. Model parameters were estimated using restricted maximum likelihood estimation [28]. Estimated intervention effects are expressed as absolute changes in the level (intercept) and trend (slope) post-implementation with 95% confidence intervals (CI), which were respectively interpreted as the immediate and gradual effects of the intervention on long-term cardiac medication adherence. Additionally, we estimated the overall effect of each intervention at 12 months post-implementation, on the absolute scale, with 95% CI by comparing the fitted post-intervention outcome response and extrapolated outcome response based only on pre-intervention data (i.e., the counterfactual trend) at the end of the study.

An identical approach to pooling and analyzing outcome data at the group-month level was taken for (1) the primary outcome in the control group and (2) each secondary outcome measuring initial duration of ≥ 90 days at index fill (per class and on average) in the intervention and control groups.

**Patient-level segmented regression analyses**

We additionally analyzed all outcomes using segmented generalized linear regression with the patient (versus group-month) as the unit of analysis and terms for time, intervention, time after intervention, and the following patient-level covariates: age; sex; primary reason for cardiac catheterization (STEMI vs NSTEMI); prior MI; prior cardiac medication use (defined as ≥ 1 dispensation for any recommended cardiac medication class within 120 days before discharge); and site (fixed effect for intervention groups; random effect for control group) [23]. We did not adjust our patient-level segmented regression analysis according to the MI-treatment received (PCI [percutaneous coronary intervention], CABG [coronary artery bypass graft surgery], or medical therapy alone) as previously published work using the same data sources, demonstrated no difference in medication adherence in these three groups [4]. For dichotomous outcomes, we specified a binary distribution with logit link and expressed intervention effects as odds ratios with 95% CI; for count-based outcomes, we specified a negative binomial distribution with log link and expressed intervention effects as rate ratios with 95% CI; and for time-to-event outcomes, we used Cox proportional hazards regression models and expressed intervention effects as hazard ratios with 95% CI. For non-fatal, time-to-event outcomes, death was treated as a censoring event [24].

**Process evaluation**

A process evaluation was undertaken to assess intervention fidelity at the (1) provider level (using the standardized prescriptions where applicable and prescribing ≥ 90 days with ≥ 3 repeats for cardiac medications) and (2) at the pharmacy level (dispensing the prescribed amount for cardiac medication prescriptions). Using local CorHealth Ontario Cardiac registry data and the approach described in the “Participants” section, we identified 731 eligible post-MI patients discharged from...
an intervention site during the 12-month implementation period: 484 from the standardized prolonged discharged prescription forms plus education intervention group (2/2 sites represented) and 247 from the education-only intervention group (2/4 sites represented). We excluded patients from the other two education-only sites due to limitations in accessing discharge prescription records at these sites. We randomly sampled 65 patients per intervention group and attempted to link their catheterization claim with their discharge hospital chart data. Among linked patients, we restricted our analysis to patients with ≥1 eligible cardiac medication discharge prescription.

Within each intervention group, hospital chart data were used to calculate the proportion of sampled patients with a prolonged discharge prescription (i.e., ≥90 days supplied with ≥3 repeats) during the intervention period for one of the four cardiac medication classes of interest. Additionally, we calculated the proportion of individuals with an average duration (i.e., days supplied per fill) of ≥90 days across all prescribed cardiac medication classes without consideration of the number of repeats. For comparison with our chart-based results, we also present the observed proportion of patients who, at their index fill, had a prolonged initial dispensation (i.e., ≥90 days supplied) per class and an average duration (i.e., days supplied) ≥90 days across all dispensed cardiac medication classes based on ODB data from the intervention period. These comparisons were intended to help us assess the level of agreement between discharge prescription duration and initial pharmacy dispensation duration. Additionally, we summarized the frequency (and proportion) of patients who received the standardized prolonged discharged prescription form as planned.

All analyses were conducted using SAS Version 9.4 (SAS Institute Inc.; Cary, NC).

Results

Study population

Between 1 September 2015 and 31 August 2018, 20,896 eligible post-MI patients across 149 hospitals were discharged following a cardiac catheterization in Ontario (Fig. 1). Additional file 1: Table S1 describes baseline patient characteristics. On average, the monthly denominator consisted of 39 (range, 28–48), 26 (range, 14–36), and 515 (range, 439–596) patients in the standardized prolonged discharge prescription forms plus education, education-only, and control groups, respectively.

Aggregate segmented regression analyses

Primary outcome

Table 1 presents estimated coefficients with 95% CI from the aggregate segmented linear regression analyses used, in part, to generate Fig. 2—which visualizes the observed time series for the monthly proportion of patients with long-term cardiac medication adherence by intervention group, along with the fitted pre- and post-implementation trends, and the extrapolated pre-implementation (i.e., counterfactual) trends.

Implementation of the standardized prolonged discharge prescription forms plus education intervention was associated with an immediate, non-statistically significant decrease of 1.08 fewer adherent patients per 100 (P = .81), and a non-significant increase of 0.54 additional adherent patients per 100 per month (P = .32) above the underlying pre-intervention trend. At 12 months post-implementation, the standardized prolonged discharge prescription forms plus education intervention was associated with a statistically insignificant increase of 5.36 additional adherent patients per 100 (95% CI −6.44 to 17.2) compared to if the intervention had never been implemented in this group.

Implementation of the education-only intervention was not associated with a statistically significant immediate (P = .74) or gradual (P = .78) change in long-term cardiac medication adherence. Similarly, at 12 months post-implementation, there was no statistically significant difference in adherence relative to the underlying counterfactual trend (1.01 additional adherent patients per 100, 95% CI −28.6 to 30.6).

In the control group, we found no immediate (P = .97) or gradual change (P = .87) in long-term cardiac medication adherence following implementation of study interventions at the other six sites. Additionally, no statistically significant difference in long-term adherence was observed at 12 months post-implementation in the control group (0.26 fewer adherent patients per 100, 95% CI −3.64 to 3.12).

Secondary outcomes

Instability in the group-specific monthly series for outcomes measuring initial durations for specific cardiac medication classes at index fill precluded modeling (results not shown). The results of our aggregate segmented linear regression analyses for the monthly proportion of patients with an average initial duration of ≥90 days across dispensed cardiac medication classes at index fill are summarized in Table 2 and visualized in Additional file 2: Fig. S1.

Implementation of the standardized prolonged discharge prescription forms plus education intervention was not associated with statistically significant immediate (P = .35) or gradual (P = .73) changes in the monthly proportion of patients receiving an average initial duration of ≥90 days across dispensed cardiac medications. At 12 months post-implementation, the standardized prolonged discharge prescription forms plus education
intervention was associated with a non-statistically significant increase of 6.19 additional patients receiving an average initial duration of ≥90 days for dispensed cardiac medications (95% CI −7.51 to 19.9) beyond the counterfactual trend.

Implementation of the education-only intervention did not correspond with statistically significant immediate (P = .34) or gradual (P = .25) changes in the monthly proportion of patients receiving an average initial duration of ≥90 days for dispensed cardiac medications. At 12 months post-implementation, the education-only intervention was associated with 2.55 fewer patients receiving an average initial duration of ≥90 days for dispensed cardiac medications (95% CI −11.5 to 6.38) over and above the counterfactual trend.

In the control group, the implementation of the interventions at non-control sites was not associated with immediate (P = .88), gradual (P = .89), or overall (at 12 months post-implementation [relative to counterfactual trend]; P = .78) changes in the monthly proportion of patients in the control group receiving an average initial duration of ≥90 days for dispensed cardiac medications.
Table 1 Results from aggregate segmented linear regression analyses estimating the absolute immediate, gradual, and overall (at 12 months post-intervention) effects of study interventions on long-term cardiac medication adherence (assessed at 1 year from hospital discharge) among post-myocardial infarction patients age 65 and older in Ontario, Canada, from September 2015 to August 2018

| Parameter                                                                 | Estimate, % (95% CI) | P value |
|---------------------------------------------------------------------------|----------------------|---------|
| **Standardized prolonged discharge prescription forms plus education (2 sites, 1414 patients)** |                      |         |
| Intercept (baseline percentage)                                           | 75.3 (70.1 to 80.4)  | <.001   |
| Pre-intervention slope (secular trend, per month)                        | −0.01 (−0.39 to 0.38) | .97     |
| Change in level post-intervention (immediate effect)                     | −1.08 (−10.7 to 8.50) | .81     |
| Change in trend post-intervention (gradual effect, per month)            | 0.54 (−0.62 to 1.70)  | .32     |
| Overall effect at 12 months post-intervention (combined immediate and gradual effect) | 5.36 (−6.44 to 17.2) | .34     |
| **Education only (4 sites, 926 patients)**                                |                      |         |
| Intercept (baseline percentage)                                           | 73.2 (60.0 to 86.4)  | <.001   |
| Pre-intervention slope (secular trend, per month)                        | 0.18 (−0.76 to 1.12)  | .65     |
| Change in level post-intervention (immediate effect)                     | −2.87 (−21.1 to 15.3) | .74     |
| Change in trend post-intervention (gradual effect, per month)            | 0.32 (−2.31 to 2.96)  | .78     |
| Overall effect at 12 months post-intervention (combined immediate and gradual effect) | 1.01 (−28.6 to 30.6) | .93     |
| **Control group (143 sites, 18556 patients)**                            |                      |         |
| Intercept (baseline percentage)                                           | 79.5 (78.0 to 80.9)  | <.001   |
| Pre-intervention slope (secular trend, per month)                        | 0.01 (−0.10 to 0.12)  | .83     |
| Change in level post-intervention (immediate effect)                     | 0.05 (−2.59 to 2.70)  | .97     |
| Change in trend post-intervention (gradual effect, per month)            | −0.03 (−0.35 to 0.30) | .87     |
| Overall effect at 12 months post-intervention (combined immediate and gradual effect) | −0.26 (−3.64 to 3.12) | .89     |

CI: confidence interval. All results based on group-specific, aggregate segmented linear regression models, which accounted for serial correlation in monthly time series data through first-order autoregressive (i.e., AR(1)) errors. AR(1) parameter estimates for each group-specific model were −0.14, 0.34, and 0.01, respectively. Model parameters were estimated using restricted maximum likelihood estimation with the Satterthwaite adjustment for computing denominator degrees of freedom. Model MSE values were 46.1, 90.1, and 2.73, respectively.

Patient-level segmented regression analyses
Additional file 3: Table S2 and Additional file 4: Table S3 summarize patient-level segmented regression analysis results for primary and secondary outcomes. The results suggest that neither intervention had immediate or gradual effects on patients’ odds of long-term cardiac medication adherence or receiving initial prescription dispensations of prolonged duration (≥ 90 days). Similarly, our results pertaining to outcomes measuring health care utilization (expressed as counts) and adverse events (time-to-event) do not suggest intervention effects (on the rate ratio and hazard ratio scales, respectively) over and above secular trends observed in the external control group.

Process evaluation
Among the randomly selected 130 patients (65 per intervention group) during the 12-month intervention period, 92 (71%) were successfully linked to their discharge hospital chart data and had ≥ 1 discharge prescription for a cardiac medication of interest. Of these patients, 41 were discharged from a site in the standardized prolonged discharge prescription forms plus education group and 51 were discharged from a site in the education-only group. The standardized prolonged discharge prescription form was only used for 44% (18/41) of sampled patients from that intervention group. Overall, 83% (34/41) and 67% (34/51) of patients in the standardized prolonged discharge prescription forms plus...
Fig. 2 (See legend on previous page.)
education and education-only groups were prescribed discharge cardiac medications with an average duration of ≥90 days per fill in the intervention period (Additional file 5: Table S4).

Table 3 summarizes group-specific proportions of patients who, at index fill, received a prolonged dispensation (i.e., ≥90 days supplied) at their local pharmacy per medication class and an average duration of ≥90 days across cardiac medication classes at index fill among post-myocardial infarction patients age 65 and older in Ontario, Canada from September 2015 to August 2018.

Table 3 Proportion of patients with a prolonged dispensation (≥90 days supplied) at index fill by cardiac medication class according to Ontario Drug Benefit claims, stratified by intervention group and study period (pre- vs post-intervention)

| Parameter | Estimate, % (95% CI) | P value |
|-----------|----------------------|---------|
| Intercept (baseline percentage) | 4.76 (−1.28 to 10.8) | .10 |
| Pre-intervention slope (secular trend, per month) | 0.04 (−0.40 to 0.47) | .83 |
| Change in level post-intervention (immediate effect) | 4.02 (−5.15 to 13.2) | .35 |
| Change in trend post-intervention (gradual effect, per month) | 0.18 (−1.06 to 1.43) | .73 |
| Overall effect at 12 months post-intervention (combined immediate and gradual effect) | 6.19 (−7.51 to 19.9) | .30 |

**Education only (4 sites, 926 patients)**

| Parameter | Estimate, % (95% CI) | P value |
|-----------|----------------------|---------|
| Intercept (baseline percentage) | 6.16 (2.25 to 10.1) | .006 |
| Pre-intervention slope (secular trend, per month) | 0.10 (−0.19 to 0.39) | .47 |
| Change in level post-intervention (immediate effect) | 3.24 (−3.89 to 10.4) | .34 |
| Change in trend post-intervention (gradual effect, per month) | −0.48 (−1.35 to 0.39) | .25 |
| Overall effect at 12 months post-intervention (combined immediate and gradual effect) | −2.55 (−11.5 to 6.38) | .54 |

**Control group (143 sites, 18556 patients)**

| Parameter | Estimate, % (95% CI) | P value |
|-----------|----------------------|---------|
| Intercept (baseline percentage) | 7.40 (6.63 to 8.17) | <.001 |
| Pre-intervention slope (secular trend, per month) | −0.02 (−0.07 to 0.04) | .57 |
| Change in level post-intervention (immediate effect) | −0.10 (−1.52 to 1.31) | .88 |
| Change in trend post-intervention (gradual effect, per month) | −0.01 (−0.18 to 0.16) | .89 |
| Overall effect at 12 months post-intervention (combined immediate and gradual effect) | −0.23 (−2.00 to 1.54) | .78 |

CI: confidence interval. All results based on group-specific, aggregate segmented linear regression models, which accounted for serial correlation in monthly time series data through first-order autoregressive (i.e., AR(1)) errors. AR(1) parameter estimates for each group-specific model were 0.22, −0.07, and −0.07, respectively. Model parameters were estimated using restricted maximum likelihood estimation with the Satterthwaite adjustment for computing denominator degrees of freedom. Model MSE values were 23.4, 22.3, and 0.88, respectively.

Index fill defined as a patient’s first prescription fill within 7 days from hospital discharge, at which point ≥1 prescriptions were filled for a statin, beta blocker, angiotensin system inhibitor, and/or secondary antiplatelet.
Discussion

To our knowledge, this is the first non-randomized interventional study to investigate how longer initial discharge prescription durations can influence medication adherence. Despite limited intervention fidelity according to process evaluation results, particularly at the pharmacy-level, we observed a 5.4% absolute increase in long-term medication adherence after 12 months post-implementation in the standardized discharge prescription forms plus education group. While this absolute difference was not statistically significant (95% CI – 6.44 to 17.2), it might be clinically important given the ease of implementation and low cost of the intervention. Further, this study highlights several important issues with respect to novel methodologies, use of individual cardiac medication classes post-MI, and policies potentially limiting the intervention fidelity.

High-quality reviews have outlined multiple barriers to medication adherence in chronic conditions, as well as interventions to mitigate these barriers at patient, health care provider, and health system levels [29–31]. Though non-adherence is a multifactorial issue, complex interventions that target multiple barriers are not very effective and difficult to sustain [30]. Therefore, evaluation of a simple health system-level intervention with even a modest impact but applied at the population level could result in significant improvements in clinical outcomes.

This simple, non-randomized intervention study was evaluated using pre-existing, routinely collected administrative data. All eligible participants in a province of over 14 million people were included in the analysis, with the vast majority discharged from a hospital in the control group. Given the limitations of the ODB database, only patients ≥ 65 years of age were included, despite the intervention being applied to all post-MI patients discharged from an intervention site during the implementation period. Therefore, given the limited number of intervention sites and age restrictions, only a fraction of eligible patients who received an intervention (standardized prolonged discharge prescription forms plus education or education-only) were analyzed. Although the findings in the combined intervention group were not statistically significant, the observed trends in long-term cardiac medication adherence over time within the intervention and control groups supports that the intervention may in fact have some value. Furthermore, the incremental improvements in long-term adherence are consistent with the varying intensity of the interventions. Specifically, at 12 months post-implementation, long-term medication adherence did not change at all in the provincial control group (0%), whereas adherence increased slightly in the education-only group (1%) and by a larger margin in the standardized prolonged discharge prescription forms plus education group (5%).

Poor intervention fidelity may have impeded the full potential for improved medication adherence in the intervention groups. As evidenced by our process evaluation, the fidelity of the intervention implementation was limited both at discharge and at the time of initial prescription fill. At discharge, only 44% of patients in the standardized prolonged discharge prescription forms plus education group received the revised study prescription as intended. The two hospital sites that implemented this two-pronged intervention used paper-based prescriptions. This format allows for deviations in prescribing practices (i.e., use of personal prescription pads or altering the standardized forms) and likely accounts for the suboptimal use of the standardized prescription forms. Despite the limited use of the standardized prescription forms, patients still received prescriptions with orders for cardiac medications to be dispensed for 90 days with repeats 83% of the time. In the education-only group, 67% of patients received prolonged cardiac prescriptions with repeats. It is hypothesized that the clinician-targeted educational outreach and reminders influenced these prescription patterns even when using non-intervention discharge prescriptions. However, barriers at the time of initial prescription fill further accounted for poor uptake of the intervention. Current prescription dispensation policies of the ODB program limit initial prescription dispensation to 30 days for new medications. However, it can be argued that the cardiac medications are not new, as they have already been initiated while participants in the study were inpatients (i.e., prior to discharge). To circumvent this policy limitation, educational outreach via personal emails and newsletters to community pharmacies in the study region was undertaken via the Ontario Pharmacy Evidence Network and the Ontario Pharmacy Evidence Network [23]. This outreach was intended to help ensure fidelity of the intervention when medications were dispensed at discharge. Furthermore, the standardized prolonged discharge prescription forms included a billing code that pharmacies could use to enable 90-day dispensation of new medications. Financial incentives are another potential barrier at the local pharmacy level. As per the ODB program [22], local pharmacies are reimbursed for up to five dispensations per patient in a 1-year period. Thus, prolonged dispensations would limit pharmacy revenues. These barriers at discharge and initial prescription fill likely accounted for the low 90-day dispensation proportions in the standardized prolonged discharge prescription forms plus education group (12%) and in the education-only group (9.5%). Unfortunately, this policy issue is not limited to Ontario [32]. Therefore, future evaluations of this intervention...
should focus on (1) restricting discharge prescriptions to an electronic health record system, which would enable control over prescribing practices and appropriate record keeping, thereby optimizing intervention fidelity within hospitals and (2) revising policies that presently limit long-term prescription dispensation at the pharmacy-level following hospital discharge.

As highlighted, poor intervention fidelity and low monthly numbers of patients in both intervention groups are key limitations of this study. Restriction of the study population to patients ≥65 years old to ensure completeness of prescription dispensation records (in the ODB database) is also a limitation that warrants consideration. Due to increased medical comorbidities and polypharmacy in older patients, the dispensation of medications may differ when compared to younger patients. For instance, the use of blister packs that limit the quantity of medications dispensed at one time is much more common for older versus younger patients. Unfortunately, random allocation of the intervention and control conditions across Ontario hospitals was not feasible. While we adjusted for several patient characteristics (including type of MI) to minimize confounding in secondary patient-level analyses, there are surely unmeasured confounders (due to non-randomized allocation) that could introduce bias into our estimated intervention effects within hospital groups and hinder between-group comparisons. Importantly, our analytic models controlled for pre-implementation (baseline) levels and trends in modeled outcomes when estimating the immediate and gradual effects of implemented interventions [33]. All measures to assess medication adherence have limitations. Although, novel methods for chemical adherence testing have been reported, these are best reserved for individual patients rather than the population level [34]. This study was designed to use pre-existing administrative datasets, therefore PDC was used and the threshold of ≥80% is associated with improved mortality in patients post-MI [10].

Conclusions

This is the first non-randomized interventional study to evaluate an intervention to standardize discharge prescriptions to prolonged duration to improve long-term medication adherence among post-MI patients. Our findings, coupled with two large scale retrospective analyses of administrative data in the USA and Canada support further evaluation of this simple intervention to improve long-term adherence to cardiac medications [4, 18]. The risks and costs are small, but the potential for clinical benefit at the population level is significant. To ensure optimal fidelity, it is recommended that a similar intervention be implemented and evaluated in a larger population with fully electronic medical records coupled with policies to support the long-term dispensation of medications at the community pharmacy-level.

Abbreviations

ACE: Angiotensin-converting enzyme inhibitor; ARB: Angiotensin receptor blocker; CABG: Coronary artery bypass graft surgery; CAD: Coronary artery disease; CI: Confidence interval; MI: Myocardial infarction; MIPAD: Myocardial Infarction Prescription Duration Study; NSTEMI: Non-ST-elevated MI; ODB: Ontario Drug Benefit; PCI: Percutaneous coronary intervention; PDC: Proportion of days covered; STEMI: ST-elevated MI.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s12916-022-02401-5.

Acknowledgements

We thank CorHealth Ontario for use of their Cardiac Registry, the Ontario Ministry of Health and Long-Term Care and IMS Brogan for use of the Ontario Drug Benefit Database, and IQVIA Solutions Canada Inc. for use of their Drug Identification Number file. Educational outreach support to community pharmacies was provided by the Ontario Pharmacists Association and Ontario Pharmacy Evidence Network.

Authors’ contributions

JDS and NI designed and supervised the study and data analysis, drafted, and reviewed all versions of this manuscript. JG, MN, and LD helped design the study, interpret the data, and revised the manuscript. ZB and MT helped design the study, drafted the analysis plan, performed preliminary analyses, and participated in writing of the manuscript. WH and FN performed analysis and provided contributions to drafting of the manuscript. KT, TM and EO provided substantive contributions to the drafting and revision of the manuscript. All authors read and approved the final submitted manuscript.
Funding
The Hamilton Academic Health Sciences Organization (HAHSO) through the AHSC AFP Innovation Fund Competition provided funding for this study. HAHSO has reviewed and approved the protocol and requires reporting on financial and results upon completion. This study was supported by ICES, which is funded by an annual grant from the Ontario Ministry of Health and Long-Term Care (MOHLTC). Parts of this material are based on data and information compiled and provided by the MOHLTC and the Canadian Institute for Health Information (CIHI). The analyses, conclusions, opinions, and statements expressed herein are solely those of the authors and do not reflect those of the funding or data sources; no endorsement is intended or should be inferred. NMI holds a Canada Research Chair in Implementation of Evidence-Based Practice. JMG holds a Canada Research Chair in Health Knowledge Transfer and Uptake.

Availability of data and materials
The dataset from this study is held securely in coded form at ICES. While data sharing agreements prohibit ICES from making the dataset publicly available, access may be granted to those who meet pre-specified criteria for confidential access, available at www.ices.on.ca/DAS. The full dataset creation plan and underlying analytic code are available from the authors upon request, understanding that the computer programs may rely upon coding templates or macros that are unique to ICES and are therefore either inaccessible or may require modification.

Declarations

Ethics approval and consent to participate
This project received ethics approval from the Hamilton Integrated Research Ethics Board (HiREB) under project #2979.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Population Health Research Institute, McMaster University and Hamilton Health Sciences, DBCVSR, 237 Barton Street East, Hamilton, ON L8L 2X2, Canada. 2Division of Cardiology, Department of Medicine, McMaster University, Hamilton, Ontario, Canada. 3Family Practice Health Centre, Women’s College Hospital, Toronto, ON, Canada. 4Department of Family and Community Medicine, University of Toronto, Toronto, ON, Canada. 5ICES, Toronto, ON, Canada. 6Epidemiology Division, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada. 7Clinical Epidemiology Program, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada. 8School of Epidemiology and Public Health, University of Ottawa, Ottawa, ON, Canada. 9Department of Medicine, University of Ottawa, Ottawa, ON, Canada. 10Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada.

Received: 5 October 2021 Accepted: 11 May 2022
Published online: 21 June 2022

References
1. Smith SC Jr, Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA, et al. AHA/ACC secondary prevention and risk reduction therapy for patients with coronary artery disease and the整治的 cardiovascular risk factors: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation. 2011;124:2458. https://doi.org/10.1161/CIR.0b013e318235eb4d.
2. Antman EM, Hand M, Armstrong PW, Bates ER, Green LA, Halasyamani LK, et al. 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association task force on practice guidelines: developed in collaboration with the Canadian cardiovascular society endorsed by the American Academy of family physicians. 2007 writing group to review new evidence and update the ACC/AHA 2004 guidelines for the Management of Patients with ST-elevation myocardial infarction, writing on behalf of the 2004 writing committee. Circulation. 2008;117:296.
3. Fitchett DH, Theroux P, Bihorly JM, Cantor WJ, Cox JL, Gupta M, et al. Assessment and management of acute coronary syndromes (ACS): a Canadian perspective on current guideline-recommended treatment—part 2: ST-segment elevation myocardial infarction. Can J Cardiol. 2011;27(Suppl A):S402.
4. Ivers NM, Schwalm JD, Jackевичius CA, Guo H, Tu Jv, Natarajan M. Length of initial prescription at hospital discharge and long-term medication adherence among elderly patients with coronary artery disease: a population-level study. Can J Cardiol. 2013;29:1408.
5. Tu Jv, Donovan LR, Lee DS, Wang JT, Austin PC, Alter DA, et al. Effectiveness of public report cards for improving the quality of cardiac care: the EFFECT study: a randomized trial. JAMA. 2009;302:2330.
6. Ahmad M, Schwalm JD, Velianou JL, Natarajan MK. Impact of routine in-hospital assessment of low-density lipoprotein levels and standardized orders on statin therapy in patients undergoing percutaneous coronary interventions. J Invasive Cardiol. 2005;17:518.
7. Newby LK, Allen Lapointe NM, Chen AY, Kramer JM, Hammill BG, Delong ER, et al. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation. 2006;113:203.
8. Hudson M, Richard H, Pilote L. Parabolas of medication use and discontinuation after myocardial infarction—are we closing the treatment gap? Pharmacoeconomics Drug Saf. 2007;16:773.
9. Shah ND, Dunlay SM, Ting HH, Montori VM, Thomas RJ, Wagle AE, et al. Long-term medication adherence after myocardial infarction: experience of a community. Am J Med. 2009;122:961.e7–961.e13.
10. Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA. 2007;297:177.
11. Ho PM, Magid DJ, Shetterly SM, Olson KL, Maddox TM, Peterson PM, et al. Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am Heart J. 2008;155:772.
12. Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation. 2009;119:3028.
13. Sabate E, editor. Adherence to long-term therapies: evidence for action. Geneva: World Health Organization; 2003.
14. Speratus JA, Kettelkamp R, Vance C, Decker C, Jones PG, Rumsfeld JM, et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation. 2006;113:2803.
15. Hope CJ, Wu J, Tu W, Young J, Murray MD. Association of medication adherence, knowledge, and skills with emergency department visits by adults 50 years or older with congestive heart failure. Am J Health Syst Pharm. 2004;61:2043.
16. Batal HA, Kranitz MJ, Dale RA, Mehler PS, Steiner JF. Impact of prescription size on statin adherence and cholesterol levels. BMC Health Serv Res. 2007;7:175 PMID: 17961256.
17. Steiner JF, Robbins LJ, Roth SC, Hammond WS. The effect of prescription size on acquisition of maintenance medications. J Gen Intern Med. 1993;8:306.
18. Rymer JA, Fonseca E, Bhandary OD, Kumar D, Khan ND, Wang TY. Difference in medication adherence between patients prescribed a 30-day versus 90-day supply after acute myocardial infarction. Am Heart J. 2020;1(1). https://doi.org/10.1161/JAHA.119.016215.
19. Presseau J, Schwalm JD, Grimshaw JM, Witterman HO, Natarajan MK, Linklater S, et al. Identifying determinants of medication adherence following myocardial infarction using the theoretical domains framework and the health action process approach. Psychol Health. 2017;32(10):1176–94.
20. Lau E, Papaioannou A, Dolovich L, Adachi J, Sawka AM, Burns S, et al. Patients’ adherence to osteoporosis therapy: exploring the perceptions of postmenopausal women. Can Fam Physician. 2008;54:394.
21. Dolovich L, Nair K, Sellers C, Lohfeld L, Lee A, Levine M. Do patients’ expectations influence their use of medication? Can Fam Physician. 2008;54(3):384.
22. Ministry of Health. Drugs and Devices Division. Section S: standard online claims. In: Ontario drug programs reference manual (edition 2, 45-48). Queen’s printer for Ontario, 2021.
23. Schwalm JD, Ivers NM, Natarajan MK, Taljaard M, Rao-Melocini P, Witteman HO, et al. Cluster randomized controlled trial of delayed educational reminders for long-term medication adherence in ST-elevation myocardial infarction (DERLA-STEMI). Am Heart J. 2015;170:903.

24. Schwalm JD, Ivers NM, Bouck Z, Taljaard M, Natarajan MK, Dolovich L, et al. Length of initial prescription at hospital discharge and long-term medication adherence for elderly, post-myocardial infarction patients: protocol for an interrupted time series study. JMIR Res Protoc. 2020;9(11):e18981.

25. Ramsay C, Matowe L, Grilli R, Grimshaw JM, Thomas RE. Interrupted time series designs in health technology assessment: lessons from two systematic reviews of behaviour change strategies. Int J Technol Assess Health Care. 2003;19(4):613–23. https://doi.org/10.1017/S0266462303000576.

26. Turner SI, Karahalios A, Forbes AB, Taljaard M, Grimshaw JM, Cheng AC, et al. Design characteristics and statistical methods used in interrupted time series studies evaluating public health interventions: a review. J Clin Epidemiol. 2020;122:1–11.

27. Kozma CM, Dickson M, Phillips AL, Meletiche DM. Medication possession ratio: implications of using fixed and variable observation periods in assessing adherence with disease-modifying drugs in patients with multiple sclerosis. Patient Prefer Adherence. 2013;12(7):509–16.

28. Turner SI, Forbes AB, Karahalios A, Taljaard M, McKenzie JE. Evaluation of statistical methods used in the analysis of interrupted time series studies: a simulation study. BMJ Open. 2019;9:e024096. https://doi.org/10.1136/bmjopen-2018-024096.

29. Choudhry NK, Kronish IM, Vongpatanasin W, Ferdinand KC, Pavlik VN, Egan BM, et al. Medication adherence and blood pressure control: a scientific statement from the American Heart Association. Hypertension. 2021;79(1):e1–e14.

30. Turner SI, Karahalios A, Taljaard M, Proctor DJ, Cheng AC, et al. Medical use of interrupted time series studies: a review. J Clin Epidemiol. 2020;122:1–11.

31. Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2014;11:CD000011. https://doi.org/10.1002/14651858.CD000011.pub4.

32. United Kingdom National Health Service. (2019). Being discharged from hospital. https://www.nhs.uk/nhs-services/hospitals/going-into-hospital/being-discharged-from-hospital.

33. Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther. 2002;27(4):299–309. https://doi.org/10.1046/j.1365-2710.2002.00430.x PMID: 12174032.

34. Lane D, Lawson A, Burns A, Azzi M, Burnier M, Jones DJL, et al. Nonadherence in hypertension: how to develop and implement chemical adherence testing. Hypertension. 2022;79(1). https://doi.org/10.1161/HYPERTENSIONAHA.121.17596 Epub 2021 Nov 5.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
- Fast, convenient online submission
- Thorough peer review by experienced researchers in your field
- Rapid publication on acceptance
- Support for research data, including large and complex data types
- Gold Open Access which fosters wider collaboration and increased citations
- Maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.
Learn more biomedcentral.com/submissions